These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 14657221)

  • 21. From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection.
    Stober CB; Lange UG; Roberts MT; Gilmartin B; Francis R; Almeida R; Peacock CS; McCann S; Blackwell JM
    Vaccine; 2006 Mar; 24(14):2602-16. PubMed ID: 16406227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Leishmania mexicana A600 genes are functionally required for amastigote replication.
    Murray AS; Lynn MA; McMaster WR
    Mol Biochem Parasitol; 2010 Aug; 172(2):80-9. PubMed ID: 20307588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LACK-reactive CD4+ T cells require autocrine IL-2 to mediate susceptibility to Leishmania major.
    Gumy A; Aseffa A; Rachinel N; Breton M; Otten L; Tacchini-Cottier F; Röcken M; Doyen N; Acha-Orbea H; Locksley RM; MacDonald HR; Launois P; Louis J
    Eur J Immunol; 2006 Jun; 36(6):1465-73. PubMed ID: 16637008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis.
    Webb JR; Kaufmann D; Campos-Neto A; Reed SG
    J Immunol; 1996 Dec; 157(11):5034-41. PubMed ID: 8943412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of parasite encoded inhibitors of serine peptidases in early infection of macrophages with Leishmania major.
    Eschenlauer SC; Faria MS; Morrison LS; Bland N; Ribeiro-Gomes FL; DosReis GA; Coombs GH; Lima AP; Mottram JC
    Cell Microbiol; 2009 Jan; 11(1):106-20. PubMed ID: 19016791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccinations with live-attenuated Leishmania major promastigotes and challenge infection with L. major in BALB/c mice.
    Onyalo JA; Mwala DM; Anjili CO; Orago AS; Tonui WK
    East Afr Med J; 2005 Apr; 82(4):193-7. PubMed ID: 16122087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogeneity of wild Leishmania major isolates in experimental murine pathogenicity and specific immune response.
    Kébaïer C; Louzir H; Chenik M; Ben Salah A; Dellagi K
    Infect Immun; 2001 Aug; 69(8):4906-15. PubMed ID: 11447167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes.
    Badiee A; Jaafari MR; Khamesipour A
    Exp Parasitol; 2007 Feb; 115(2):127-34. PubMed ID: 16979165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leishmania major MAP kinase 10 is protective against experimental L. major infection.
    Kumari S; Singh S; Saha B; Paliwal PK
    Vaccine; 2011 Nov; 29(48):8783-7. PubMed ID: 21527301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcineurin is required for Leishmania major stress response pathways and for virulence in the mammalian host.
    Naderer T; Dandash O; McConville MJ
    Mol Microbiol; 2011 Apr; 80(2):471-80. PubMed ID: 21320183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a compensatory mutant (lpg2-REV) of Leishmania major able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies.
    Späth GF; Lye LF; Segawa H; Turco SJ; Beverley SM
    Infect Immun; 2004 Jun; 72(6):3622-7. PubMed ID: 15155672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leishmania major parasite stage-dependent host cell invasion and immune evasion.
    Wenzel UA; Bank E; Florian C; Förster S; Zimara N; Steinacker J; Klinger M; Reiling N; Ritter U; van Zandbergen G
    FASEB J; 2012 Jan; 26(1):29-39. PubMed ID: 21908716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antigen requirements for efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells.
    Bertholet S; Debrabant A; Afrin F; Caler E; Mendez S; Tabbara KS; Belkaid Y; Sacks DL
    Infect Immun; 2005 Oct; 73(10):6620-8. PubMed ID: 16177338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunization with persistent attenuated Delta lpg2 Leishmania major parasites requires adjuvant to provide protective immunity in C57BL/6 mice.
    Kébaïer C; Uzonna JE; Beverley SM; Scott P
    Infect Immun; 2006 Jan; 74(1):777-80. PubMed ID: 16369039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional plasticity of the LACK-reactive Vbeta4-Valpha8 CD4(+) T cells normally producing the early IL-4 instructing Th2 cell development and susceptibility to Leishmania major in BALB / c mice.
    Maillard I; Launois P; Himmelrich H; Acha-Orbea H; Diggelmann H; Locksley RM; Louis JA
    Eur J Immunol; 2001 Apr; 31(4):1288-96. PubMed ID: 11298356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phenotypic changes associated with deletion and overexpression of a stage-regulated gene family in Leishmania.
    McKean PG; Denny PW; Knuepfer E; Keen JK; Smith DF
    Cell Microbiol; 2001 Aug; 3(8):511-23. PubMed ID: 11488813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
    Bretscher PA; Ogunremi O; Menon JN
    Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leishmania-derived murine monocyte chemoattractant protein 1 enhances the recruitment of a restrictive population of CC chemokine receptor 2-positive macrophages.
    Conrad SM; Strauss-Ayali D; Field AE; Mack M; Mosser DM
    Infect Immun; 2007 Feb; 75(2):653-65. PubMed ID: 17088347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK.
    Pinto EF; Pinheiro RO; Rayol A; Larraga V; Rossi-Bergmann B
    Infect Immun; 2004 Aug; 72(8):4521-7. PubMed ID: 15271911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistence without pathology in phosphoglycan-deficient Leishmania major.
    Späth GF; Lye LF; Segawa H; Sacks DL; Turco SJ; Beverley SM
    Science; 2003 Aug; 301(5637):1241-3. PubMed ID: 12947201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.